hotspot -WSS

hotspot

author：Wikipedia 2025-09-05 13:47:54 - browse：46783

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Inari Medical to buy amputation prevention company LimFlow

focus

WSS

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

United colonoscopy coverage change 'may cost lives,' doctors say

Live blog: Hearing on CRISPR

United colonoscopy coverage change 'may cost lives,' doctors say

Hepatitis C has a cure — but many Americans still lack access to it

Cancer drug shortages should be causing more outrage

hotspot

hotspot

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Life sciences investors close nearly $6 billion in new funds

State Dept. review finds Biden bears some blame for Afghanistan failures

What does generative AI mean for health care? We asked experts

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Dobbs anniversary: the lost opportunity of abortion as health care

ChatGPT in medicine: STAT answers readers' burning questions

How to convince healthy people to buy insurance

Trump demands the U.S. pay no more for drugs than other countries … again

Hepatitis C has a cure — but many Americans still lack access to it

entertainment

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

The high cost of giving birth even with insurance

Kidney transplant patients stopped immunosuppressants in trial

Inari Medical to buy amputation prevention company LimFlow

Gene therapy’s promise and the high cost of hope

Bill would allow buprenorphine prescription for addiction via telehealth

explore

explore

focus

Wikipedia